Explainable Artificial Intelligence in Pharmaceutical Out-of-Specification Investigations: A Critical Review of Root Cause Analysis, Risk-Based Decision Support, and GMP Compliance

Authors

  • Satish Kumar Sarankar
  • Sushma Somkuwar

Keywords:

Data integrity, Explainable artificial intelligence, GMP compliance, Out-of-specification, Pharmaceutical quality control, Quality risk management, Root cause analysis, SHAP

Abstract

Abstract

Background: Out-of-specification (OOS) results are critical pharmaceutical quality events requiring scientifically justified investigations, comprehensive documentation, and appropriate corrective and preventive actions. Conventional investigations depend on laboratory record review, investigator experience, established root cause analysis techniques, and the assessment of manufacturing-related variables. Although Artificial Intelligence (AI) offers opportunities to analyze complex quality datasets, the limited interpretability of many machine learning models presents challenges for regulated pharmaceutical decision-making.

Objective: This review critically examines the potential applications, scientific limitations, validation requirements, and regulatory implications of explainable artificial intelligence in pharmaceutical OOS investigations.

Methods: A targeted critical review was developed using publicly accessible regulatory documents, foundational XAI literature, and relevant publications addressing pharmaceutical quality systems, laboratory investigations, AI-assisted analysis, and root cause assessment.

Discussion: XAI techniques, including SHapley Additive exPlanations (SHAP), Local Interpretable Model-Agnostic Explanations (LIME), interpretable decision trees, counterfactual explanations, and causal modeling, may assist investigators in identifying influential variables and prioritizing investigative hypotheses. However, predictive associations cannot independently establish causation or justify the invalidation of an OOS result. A proposed evidence-controlled XAI–OOS framework integrates data integrity assessment, model-based hypothesis generation, explanation reliability, scientific verification, human review, and quality-unit authorization. Regulatory considerations include FDA OOS guidance, ICH Q9(R1), ICH Q10, computerized-system controls, and emerging AI governance expectations.

Conclusion: Explainable AI may support more consistent and evidence-informed pharmaceutical investigations when deployed within a validated, risk-based, human-supervised quality system. Prospective studies are necessary to establish its effectiveness, reliability, and operational suitability.

Published

2026-11-16